Simvastatin alleviates ConA-induced autoimmune hepatitis by inhibiting CD4+T cell activation via calcium-NFATC3 pathway

The mevalonate pathway plays a crucial role in various immune disease and Hmgcr is the key enzyme of this pathway. In addition, simvastatin, as an inhibitor of Hmgcr , also exhibits therapeutic potential for acute liver injury such as APAP-induced toxicity and hepatic ischemia-reperfusion injury (HIRI). However,its effect in ConA-induced acute liver injury remains unclear. Overall design: To investigate the role of simvastatin on CD4+ T cells in the progression of ConA-induced liver injury, CD4+ T cells from liver tissue of the mice which were treated with or without simvastatin were performed mRNA transcriptome sequencing.